Table 2 SOX-targeted therapeutics.
Compounds | Target | Biomarker | Cancer | Mechanism | Reference |
|---|---|---|---|---|---|
BAY-11-7082 | CXCL1 | SOX4 | Breast cancer | Inhibits the EMT process via blocking NF-κB pathway | [146] |
Rapamycin | mTOR | SOX2, SOX9 | GBM | Inhibits the properties of GSCs | [177] |
Gemcitabine | EGFR | SOX9 | PaC | Inhibits the metastasis of PaC via inhibiting EGFR/FOXA2/SOX9 axis | [179] |
Luoteolin | PI3K/AKT | SOX2 | ESCC | Downregulates SOX2 through inhibition of the PI3K/AKT signaling pathway | [174] |
Thiolutin | PSMD14 | SOX2 | HNSCC | Promotes chemosensitivity via inhibiting E2F1/AKT/SOX2 axis | [175] |
P42 | SOX2 | SOX2 | ESCC | Interacts with SOX2 via a constrained peptide expression cassette | [180] |
ZF-ATFs | SOX2 | SOX2 | / | Binds to the promoter of SOX2 with a transcriptional repressor SKD domain. | [181] |
Peptide | S9pep | / | Colon cancer | Mimics SOX9 tumor-suppressive properties and inhibit colon cancer cell growth | [182] |
S6pep | / | GBM | Induces SOX6 peptide-specific cytotoxic T lymphocytes, lyse GSCs derived from GBM. | [183] | |
S11pep | / | Glioma | Generates SOX11-specific CD8 + T cells | [184] |
